CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

Autor: CatalYm
Zdroj: Business Wire (English). 10/15/2023.
Abstrakt: CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance. The results will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain on Sunday, October 22nd by CatalYm’s CSO, Dr. Christine Schuberth-Wagner. The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages. These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity. [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Nepřihlášeným uživatelům se plný text nezobrazuje